Chronic kidney disease burden from 1990 to 2023 in China: national and provincial insights from the Global Burden of Diseases study 2023 [0.03%]
中国1990至2023年慢性肾脏疾病疾病负担：全球疾病负担研究2023年中国及各省情况分析
Guanhao He,Jiangmei Liu,Yi Lin et al.
Guanhao He et al.
Background: Chronic kidney disease (CKD) is known as a silent killer and poses considerable disease burden. This study aimed to assess the disease burden of CKD in China and its provinces from 1990 to 2023. ...
Combating dengue using male Wolbachia- infected mosquitoes-lessons from Singapore's experience [0.03%]
新加坡用雄性沃尔巴克氏体感染的蚊子防控登革热的经验教训
Jue Tao Lim,Vernon J Lee,Cheong Huat Tan et al.
Jue Tao Lim et al.
Dynamic, quantitative ESAT6-CFP10 skin test for tuberculosis risk prediction: a large-scale, multi-center, prospective cohort study [0.03%]
定量动态ESAT-6/CFP10皮试在结核病风险预测中的应用价值：一项大规模、多中心前瞻性队列研究
Peng Lu,Zhongqi Li,Bilin Tao et al.
Peng Lu et al.
Background: Predicting which individuals with M. tuberculosis (M. tb) infection will progress to active disease remains challenging. We evaluated whether a pragmatic serial, quantitative ESAT6-CFP10 (EC) antigen-based ski...
G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination [0.03%]
印尼G6PD缺乏症的系统性综述及疟疾消除背景下的变异地图更新
Arkasha Sadhewa,Lydia Visita Panggalo,Illene Nanine et al.
Arkasha Sadhewa et al.
Background: Low-daily-dose primaquine (PQ) (0·25 mg/kg/day over 14 days) remains the first-line treatment for P. vivax hypnozoites in Indonesia but can trigger haemolysis in glucose-6-phosphate dehydrogenase (G6PD) defic...
Social network distribution of HIV self-tests among MSM in Australia: a prospective, non-randomised trial [0.03%]
澳大利亚MSM中HIV自我检测的社会媒体分发情况：一项前瞻性非随机对照试验
Ying Zhang,Cheryl C Johnson,Michael Traeger et al.
Ying Zhang et al.
Background: HIV testing uptake among men who have sex with men (MSM) in Australia remains suboptimal, with lapses and extended testing intervals persisting despite established guidelines. Novel HIV testing strategies addr...
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study [0.03%]
Savolitinib治疗中国MET外显子14突变的局部晚期或转移性非小细胞肺癌患者疗效和安全性：一项确证性III期研究最终结果
Yongfeng Yu,Qisen Guo,Yongchang Zhang et al.
Yongfeng Yu et al.
Background: Savolitinib, a potent MET inhibitor, showed promising efficacy and tolerable safety in a Phase 3b confirmatory trial for the treatment of Chinese patients with non-small cell lung cancer (NSCLC) harbouring MET...
Mass hepatitis C virus screening among persons in custody in Hong Kong: a modelling cost-effectiveness analysis based on a prospective cohort study [0.03%]
基于前瞻性队列研究的香港在管人群大规模丙型肝炎病毒筛查的成本效益模型分析
Zonglin Dai,Kai-Tai Wong,Edgar Chow et al.
Zonglin Dai et al.
Background: Persons in custody (PICs) have a disproportionately high rate of hepatitis C virus (HCV) infection, yet correctional elimination programmes remain scarce. We evaluated the cost-effectiveness of different priso...
Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China [0.03%]
比克泰韦/恩曲他滨/特诺福韦艾拉酚胺伏马酯与多替拉韦为基础的抗逆转录病毒疗法治疗HIV感染者效果及死亡率：中国多中心回顾性队列研究
Xinsheng Wu,Ping Ma,Lianguo Ruan et al.
Xinsheng Wu et al.
Background: Large-scale, multicenter, long-term real-world studies investigating the associations between bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) (B/F/TAF) versus dolutegravir (DTG)-base...
Corrigendum to "Incidence and associated factors of major VCI in first-ever ischemic stroke patients with mild VCI: a five-year prospective cohort study" [The Lancet Regional Health - Western pacific Volume 67, February 2026, 101800] [0.03%]
“轻度血管性认知障碍首次缺血性卒中患者的大血管性认知障碍的发生率及影响因素：一项五年前瞻性队列研究”的勘误(The Lancet Regional Health - Western Pacific，2023年2月，Volume 67, 101800)
Ho Seok Lee,Min Kyun Sohn,Jongmin Lee et al.
Ho Seok Lee et al.
[This corrects the article DOI: 10.1016/j.lanwpc.2026.101800.]. © 2026 The Author(s).
Lessons from developing the Papua New Guinea National Health Research Agenda 2025-2030 [0.03%]
巴布亚新几内亚国家卫生研究议程（2025-2030）的制定经验分享
Manah Dindi,Greco B Malijan,Gui Xian Ong et al.
Manah Dindi et al.